Compare Crispr Therapeutics AG (CRSP) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Dicks Sporting Goods Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Dicks Sporting Goods Inc trades at $136.65 (market cap $13.26B). The key difference: Dicks Sporting Goods Inc is far larger — about 2.7× Crispr Therapeutics AG's market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Dicks Sporting Goods Inc for 19 Days on average.
| CRSP | DKS | |
|---|---|---|
Market Cap | $4.88B | $13.26B |
Volume | 2,861,747 | 2,292,035 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $239.17 |
52-Week Low | $44.34 | $121.15 |
Typical Hold Time | 77 Days | 19 Days |
Enterprise Value | $3.30B | $20.31B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
DICK'S Sporting Goods (DKS) trades at $136.65, up 4.17% today, with a bearish technical signal but strong fundamentals including a P/E of 14.86 and ROE of 18.47%. Recent earnings show mixed results, with Q2 2026 missing estimates, while Q3 2026 results are pending. The company faces a securities class action lawsuit, with multiple law firms alerting investors of a November 2026 deadline, contributing to negative sentiment despite a dividend announcement of $1.25 payable in September 2026.
The outlook is cautious due to legal overhangs and a bearish technical trend, but valuation metrics remain attractive. Upside exists if the company exceeds Q3 earnings expectations and resolves legal issues. Key risks include the class action lawsuit, competitive pressures, and potential margin compression from increased investing activities. Analyst consensus is bullish with a $153.30 price target, suggesting 12% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
